| Literature DB >> 28095904 |
Sheri A Lippman1,2, Audrey Pettifor3,4, Dumisani Rebombo5, Aimée Julien3,4, Ryan G Wagner3,6, Mi-Suk Kang Dufour7, Chodziwadziwa Whiteson Kabudula3,8, Torsten B Neilands7, Rhian Twine3, Ann Gottert4, F Xavier Gómez-Olivé3, Stephen M Tollman3, Ian Sanne9, Dean Peacock5,10, Kathleen Kahn3,6.
Abstract
BACKGROUND: HIV transmission can be decreased substantially by reducing the burden of undiagnosed HIV infection and expanding early and consistent use of antiretroviral therapy (ART). Treatment as prevention (TasP) has been proposed as key to ending the HIV epidemic. To activate TasP in high prevalence countries, like South Africa, communities must be motivated to know their status, engage in care, and remain in care. Community mobilization (CM) has the potential to significantly increase uptake testing, linkage to and retention in care by addressing the primary social barriers to engagement with HIV care-including poor understanding of HIV care; fear and stigma associated with infection, clinic attendance and disclosure; lack of social support; and gender norms that deter men from accessing care. METHODS/Entities:
Keywords: Cluster randomized trial; Community mobilization; Engagement in care; HIV testing; Retention in care; South Africa; Treatment as prevention
Mesh:
Year: 2017 PMID: 28095904 PMCID: PMC5240325 DOI: 10.1186/s13012-016-0541-0
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Fig. 1Map of the Agincourt Health and Socio-Demographic Surveillance System (Agincourt HDSS) and surrounding area
Fig. 2Conceptual framework of the intervention, community mobilization components, and study goals
Intervention activities addressing social barriers to treatment as prevention, mapped onto community mobilization domains
| Social barriers to TasP | ||||
|---|---|---|---|---|
| CM domains | Stigma related to testing, care, and treatment | Increased knowledge (diminish fears) about testing and treatment | Gender norms around testing and treatment | Social support around testing and treatment |
| Building shared concerns and | *2-Day intensive and single session workshops | *Street theater-focused on barriers to testing/treatment | *2-Day and intensive and single session workshops on gender norms and the benefits/barriers to men engaging in testing and care | *2-Day intensive and single session group workshops-focused on community barriers to testing and treatment |
| Engaging leadership and stakeholders | *Engaging leaders around importance of TasP and barriers in community | *Engaging leaders around importance of TasP and barriers in community | *Engaging leaders around the importance of men engaging in health care | *Identifying home based care support groups in CAT development |
| Orgs/networks (includes NGOs, CBOs, CATs, other family or community groups/networks) | *Working with the key groups to openly support and include testing and treatment in their work in the communities | *Working with key groups to understand how testing and care can improve community well-being | *Working with the key groups (employers, small businesses, sport teams, etc..) to support engagement of men in testing/care | *Identifying home-based care groups and PLWH in CAT development *Partnering with support and treatment networks |
| Collective action | *Murals that address stigma related to testing and treatment | *Soccer tournaments that highlight importance of testing and treatment | *Community events/forums that address gender norms and accessing HIV care *Murals that address gender norms and HIV care | *Community events conducted by CATS, PLWH, and home-based care groups to increase community support around TaSP |
| Social cohesion | *Visible community support (events/forums) to reduce stigma–working with PLWH | *Identifying home based care groups and PLWH in CAT development–providing safe space for discussion and support | *Dialogues with men’s groups or associations–addressing male support for testing/care. | *Work with home-based care and CATS to establish PLWH support networks |
Fig. 3Study design and data collection components
Summary of quantitative data elements
| Domain | Instrument/measure | Data source and frequency |
|---|---|---|
| Primary exposure | ||
| Village | Village of residence (binary; intervention vs. control village) | HDSS-annual |
| Primary outcomes | ||
| Testing uptake (aim 1) | Binary: tested/untested past 12 months, among HIV-negative or unknown status residents | Electronic health facility records-ongoing |
| Binary: known HIV status–either confirmed positive or tested within the last 12 months | Electronic health facility records-ongoing | |
| Linkage to HIV care (aim 2) | Binary: received baseline CD4 results and evidence of follow-up care (additional CD4, viral load, or treatment initiation) within 3 months of testing HIV positive | Electronic health facility records-ongoing |
| Binary: treatment initiation within 3 months of positive diagnosis among those eligible for ART | Electronic health facility records-ongoing | |
| Retention in HIV care (aim 3) | Binary: HIV patients on or initiating ART who have no more than a 90-day gap in medication received in the 12-month period (no defaulting). | Electronic health facility records-ongoing |
| Binary: HIV patients not ART eligiblea who have a repeat CD4 test 6–12 months after initial CD4 | Electronic health facility records-ongoing | |
| Meditator/mechanism | ||
| Community mobilization | Six domains of community mobilization measure [ | Population-based surveys (years 1 and 5) |
| Covariates | ||
| Demographics | Age, SES, gender, migration status | HDSS-annual |
| Social norms | Stigma [ | Population-based surveys (years 1 and 5) |
| Secondary outcomes | ||
| Testing (aim 1) | Median CD4 of people initiating ART (to explore earlier testing, entry into care) | Electronic health facility records-ongoing |
| Re-engagement in care (aims 2 and 3) | Patients out of care (not retained) who are re-engaged in care (have a CD4 test/initiate or re-initiate treatment). | Electronic health facility records-ongoing |
| Viral suppression | Proportion of residents with viral load <400 copies/ml | Electronic health facility records-ongoing |
| Secondary exposure | ||
| Intervention coverage | Reported exposure to intervention events | Population-based surveys (years 1 and 5) |
aPrior to September 2016, patients were considered ART eligible with one or more of the following criteria: pregnancy, CD4 count lower than 500 cells/mm [3], active tuberculosis, WHO stage 3 or 4, or initiation of ART per clinician discretion. Universal treatment was planned to be instituted in September 2016; therefore, all HIV-positive individuals will be considered treatment eligible after this date; the pre-ART definition will only apply to the period prior to implementation of the universal treatment guidelines
Power calculations–minimum detectable effects
| Outcomes: proportion of population | Current estimate | Intervention group target | Minimum detectable difference (proportion) |
|---|---|---|---|
| Testing; tested in past 12 months | 35% | 60% | 19% |
| Linkage; undergoing CD4 staging within 3 months of positive test | 65% | 85% | 18% |
| Linkage; eligible for ART who initiate treatment within 3 months | 60% | 80% | 19% |
| Retention; HIV positive who remain in care at 12 months | 50% | 70% | 19% |